Lixisenatide for the treatment of type 2 diabetes

A B Petersen, F K Knop, M Christensen

18 Citations (Scopus)


Lixisenatide (trade name Lyxumia®), a short-acting glucagon-like peptide 1 receptor (GLP-1R) agonist, was approved for the treatment of type 2 diabetes by the European Medicines Agency in early 2013. In preclinical investigations, acceptable toxicity and carcinogenicity profiles were demonstrated, as well as pancreatic beta cell-preserving actions and favorable effects on glycemic control. Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours. In clinical trials of up to 1 year duration in patients with type 2 diabetes, treatment with lixisenatide alone and in combination with insulin and various oral antidiabetics conferred significant reductions in HbA1c, fasting and postprandial plasma glucose. In direct comparison with the other GLP-1R agonists on the market (exenatide and liraglutide), lixisenatide appears to be less efficient, or at best non-inferior in terms of reducing HbA1c, fasting plasma glucose and body weight. Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia.
Original languageEnglish
JournalDrugs of Today
Issue number9
Pages (from-to)537-53
Number of pages17
Publication statusPublished - Sep 2013


  • Animals
  • Blood Glucose
  • Body Weight
  • Diabetes Mellitus, Type 2
  • Drug Evaluation, Preclinical
  • Drug Interactions
  • Half-Life
  • Humans
  • Hypoglycemic Agents
  • Peptides


Dive into the research topics of 'Lixisenatide for the treatment of type 2 diabetes'. Together they form a unique fingerprint.

Cite this